Global biopharmaceutical CEOs response to reforms introduced in Germany
In response to reforms adopted by the German government on 10 July, BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said:
“The legislation passed by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines. Failing to reflect the value that medicines and vaccines bring, will negatively impact the availability of new medicines for patients and lead to reduced levels of investment in research and development.
The German Government must act to reverse the current direction which undermines Germany’s position as a leading location for pharmaceutical innovation and investment.”
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
